Skip to main content
Publications
Hanna MG, Badrising UA, Benveniste O, Lloyd TE, Needham M, Chinoy H, Aoki M, Machado PM, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AL, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Katsuno M, Murata K, Nodera H, Nishino I, Romano C , Williams VSL , Vissing J, Zhang Auberson L, Wu M, de Vera A, Papanicolaou DA, Amato AA, RESILIENT Study Group. Safety and efficacy of intravenous bimagrumab in inclusion body myositis: a phase 2b, randomised, double-blind, placebo-controlled study (RESILIENT) . Lancet Neurol. 2019 Sep;18(9):834-44.
Alonso V, Escudero P, Fernandez-Martos C, Salud A, Mendez M, Gallego J, Rodriguez JR, Martin-Richard M, Fernandez-Plana J, Manzano H, Mendez JC, Zanui M, Falco E, Gil-Raga M, Rojo F, Cuatrecasas M, Feliu J, Garcia-Albeniz X , Maurel J. Coexpression of p-IGF-1R and MMP-7 modulates panitumumab and cetuximab efficacy in RAS wild-type metastatic colorectal cancer patients . Neoplasia. 2018 Jul;20(7):678-86. doi: 10.1016/j.neo.2018.05.004
Cronin-Fenton DP, Kjaersgaard A, Norgaard M, Pedersen IS, Thomassen M, Kaye JA, Gutierrez L , Telford C, Lewis J, Tyczynski JE, Sorensen HT. Clinical outcomes of female breast cancer according to BRCA mutation status . Cancer Epidemiol Biomarkers Prev. 2017 Aug;49:128-37. doi: 10.1016/j.canep.2017.05.016
Palmieri RT, Wilson MA, Iversen ES, Clyde MA, Calingaert B , Moorman PG, Poole C, Anderson AR, Anderson S, Anton-Culver H, Beesley J, Hogdall E, Brewster W, Carney ME, Chen X, Chenevix-Trench G, Chang-Claude J, Cunningham JM, DiCioccio RA, Doherty JA, Easton DF, Edlund CK, Gayther SA, Gentry-Maharaj A, Goode EL, Goodman MT, Kjaer SK, Hogdall CK, Hopkins MP, Jenison EL, Blaakaer J, Lurie G, McGuire V, Menon U, Moysich KB, Ness RB, Pearce CL, Pharoah PDP, Pike MC, Ramus SJ, Rossing MA, Song H, Terada KY, VanDenBerg D, Vierkant RA, Wang-Gohrke S, Webb PM, Whittemore AS, Wu AH, Ziogas A, Berchuck A, Schildkraut JM. Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women . Cancer Epidemiol Biomarkers Prev. 2008 Dec 1;17(12):3567-72.
Schildkraut JM, Moorman PG, Bland AE, Halabi S, Calingaert B , Whitaker R, Lee PS, Elkins-Williams T, Bentley RC, Marks JR, Berchuck A. Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup . Cancer Epidemiol Biomarkers Prev. 2008 Mar 1;17(3):585-93.
Schildkraut JM, Murphy SK, Palmieri RT, Iversen E, Moorman PG, Huang Z, Halabi S, Calingaert B , Gusberg A, Marks JR, Berchuck A. Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer . Cancer Epidemiol Biomarkers Prev. 2007 Mar 1;16(3):473-80.
Fortuny J , Kogevinas M, Garcia-Closas M, Real FX, Tardon A, Garcia-Closas R, Serra C, Carrato A, Lloreta J, Rothman N, Villanueva C, Dosemeci M, Malats N, Silverman D. Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain . Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1696-702. doi: 10.1158/1055-9965.EPI-06-0038
Fortuny J , de Sanjose S, Becker N, Maynadie M, Cocco PL, Staines A, Foretova L, Vornanen M, Brennan P, Nieters A, Alvaro T, Boffetta P. Statin use and risk of lymphoid neoplasms: results from the European Case-Control Study EPILYMPH . Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):921-5. doi: 10.1158/1055-9965.EPI-05-0866 PMID 16702371
Berchuck A, Schildkraut JM, Wenham RM, Calingaert B , Ali S, Henriott A, Halabi S, Rodriguez GC, Gertig D, Purdie DM, Kelemen L, Spurdle AB, Marks J, Chenevix-Trench G. Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers . Cancer Epidemiol Biomarkers Prev. 2004 Dec 1;13(12):2141-7.